Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Margaret Tempero
Headshot of Margaret Tempero
Margaret Tempero

Description

Summary

This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the body and cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trametinib together with hydroxychloroquine may work better in treating patients with pancreatic cancer.

Official Title

THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic Cancer

Details

PRIMARY OBJECTIVES:

  1. To determine the recommended phase II dose of hydroxychloroquine in combination with trametinib as assessed by the occurrence of dose-limiting toxicities (DLTs).

Keywords

Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Pancreatic Carcinoma, Carcinoma, Pancreatic Neoplasms, Hydroxychloroquine, Trametinib

Eligibility

Locations

  • UCSF accepting new patients
    San Francisco California 94143 United States
  • Huntsman Cancer Institute/University of Utah accepting new patients
    Salt Lake City Utah 84112 United States

Lead Scientist at UCSF

  • Margaret Tempero
    Margaret Tempero, MD, is a Professor of Medicine and Director of the UCSF Pancreas Center and editor-in-chief of JNCCN. Her research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. Dr. Tempero has served on the ASCO Board of Directors and as ASCO President. She currently serves on the ASCO Conquer Cancer Foundation Board.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of Utah
ID
NCT03825289
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 39 study participants
Last Updated